Treadwell Therapeutics

Treadwell Therapeutics is a clinical-stage biotechnology company focused on developing innovative oncology therapeutics and small molecule drugs to meet the unmet needs of cancer patients. Founded in 2019 and based in New York, the company has established a robust pipeline that includes notable candidates such as CFI-400945, a first-in-class PLK4 kinase inhibitor, CFI-402257, a best-in-class TTK inhibitor, and CFI-402411, an oral immunomodulatory inhibitor targeting HPK1. Treadwell also engages in pre-clinical development of various biologic and next-generation TCR-based autologous cell therapy programs. With a team of experienced experts in drug discovery and clinical development, Treadwell aims to exploit cancer cell vulnerabilities and enhance recovery outcomes for patients.